BKYI (BIO-key International) Cash And Cash Equivalents : $0.44 Mil (As of Dec. 2024)

View and export this data going back to 1997. Start your Free Trial

What is BIO-key International Cash And Cash Equivalents?

BIO-key International's quarterly cash and cash equivalents increased from Jun. 2024 ($1.26 Mil) to Sep. 2024 ($1.80 Mil) but then stayed the same from Sep. 2024 ($1.80 Mil) to Dec. 2024 ($0.44 Mil).

BIO-key International's annual cash and cash equivalents declined from Dec. 2022 ($2.64 Mil) to Dec. 2023 ($0.51 Mil) and declined from Dec. 2023 ($0.51 Mil) to Dec. 2024 ($0.44 Mil).

BIO-key International Cash And Cash Equivalents Historical Data

The historical data trend for BIO-key International's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BIO-key International Cash And Cash Equivalents Chart

BIO-key International Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

16.99

7.75

2.64

0.51

0.44

BIO-key International Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash And Cash Equivalents	Get a 7-Day Free Trial															0.51	0.69	1.26	1.80	0.44

BIO-key International Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

BIO-key International (NAS:BKYI) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

BIO-key International Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of BIO-key International's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

BIO-key International Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Industrials » Business Services » BIO-key International Inc (NAS:BKYI) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

3349 Highway 138, Building A, Suite E, Wall, NJ, USA, 07719

Website

https://www.bio-key.com

BIO-key International Inc is a fingerprint biometric technology company. It develops and markets fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing hardware and software solutions. Its product portfolio comprises SideSwipe, SidePass, EcoID, WEB-key, and others. The company generates its revenue in the form of Services, License fees, and others.

Executives

Michael W Depasquale	director, officer: Co-Chief Executive Officer	1285 CORPORATE CENTER DR, STE 175, EAGAN MN 55121
James David Sullivan	officer: See Remarks	411 WALNUT ST., PMB #15855, GREEN COVE SPRINGS FL 32043
Cameron E. Williams	director	400 N. CASCADES CIRCLE, CANTON GA 30114
Fong Wong Kwok	director	FLAT C, 27/F., BLOCK 5, GRAND PACIFIC VIEWS, SIU LAM K3 00000
Emmanuel Alia	director	15 C SIGNAL HILL ROAD, MADISON CT 06443
Robert J Michel	director	C/O ASTA FUNDING, INC., 210 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Micron Technology Development Ltd	10 percent owner	5/F., SPA CENTRE, 53-55 LOCKHART ROAD, WANCHAI K3 999077
Yick Fabian Shin	director	FLAT B, 23/F, TOWER 2B, 19 TONG YON ST.,, THE WINGS IIIA, TSEUNG KWAN O., NEW TERRITORIES K3 00000
Knook Pieter Cornelis	director	3349 HIGHWAY 138, BUILDING A, SUITE E, WALL NJ 07719
Jianhui Yao	director	SUITES 2601-2, 26/F TOWER 2, NINA TOWER, 8 YEUNG UK RD, TSUEN WAN K3 TWTL 353
Barbara Rivera	director	C/O BIO-KEY INTERNATIONAL, INC., 3349 HIGHWAY 138, BUILDING A, SUITE E, WALL NJ 07719
Thomas Gilley	director	C/O BIO-KEY INTERNATIONAL, INC., 3349 HIGHWAY 138, BUILDING A, SUITE E, WALL NJ 07719
Iii Thomas Bush,	director	C/O BIO-KEY INTERNATIONAL, INC., 3349 HIGHWAY 138, BUILDING A, SUITE E, WALL NJ 07719
Cecilia C Welch	officer: Chief Financial Officer	PO BOX 588, DUNSTABLE MA 01827
John Schoenherr	director	C/O ORACLE CORPORATION, 10 VAN DE GRAAFF DRIVE, BURLINGTON MA 01803